Center | Disease | Status of disease | Activation motif of CAR | Drugs | Numbers of CAR-T cells | Phase | Status | Registered ID |
---|---|---|---|---|---|---|---|---|
National Cancer Institute (NCI), American | B cell cancer | Either did not respond to or recurred after allogeneic transplantation | Not shown | Cy 180Â mg/m2 for 3Â days and pentostatin 4Â mg/m2 for 1Â day | Dose escalation | I | Suspended | NCT01087294 |
University of Pennsylvania, American | CD19+ ALL | Relapse after allogeneic transplantation | 4-1BB | Not shown | Not shown (split infusion over 3Â days) | I | Completed | NCT01551043 |
Department of Hematology, Xinqiao Hospital, China | B-ALL | Molecular relapse after allogeneic transplantation | Not shown | No | 1 × 106/kg | II | Recruiting | ChiCTR-OOC-16008447 |